Primary Outcome Measures
Radiographic Progression-free Survival (rPFS) [Time Frame: From enrollment to primary completion of study (up to approximately 5 years)] [Designated as safety issue: ]
Secondary Outcome Measures
Objective Response Rate (ORR) [Time Frame: From enrollment to primary completion of study (up to approximately 5 years)] [Designated as safety issue: ]
Duration of Response (DOR) [Time Frame: From enrollment to primary completion of study (up to approximately 5 years)] [Designated as safety issue: ]
Time to Prostate Specific Antigen (PSA) Progression [Time Frame: From enrollment to primary completion of study (up to approximately 5 years)] [Designated as safety issue: ]
PSA Response [Time Frame: From enrollment to primary completion of study (up to approximately 5 years)] [Designated as safety issue: ]
Change in Patient-reported Outcome (PRO) [Time Frame: From enrollment to primary completion of study (up to approximately 5 years)] [Designated as safety issue: ]
Clinical Benefit Rate (CBR), defined as the percentage of patients with a complete response (CR), partial response (PR), and stable disease (SD) according to modified RECIST Version 1.1 with no progression in bone per PCWG3 criteria [Time Frame: From enrollment to primary completion of study (up to approximately 5 years)] [Designated as safety issue: ]
Overall Survival [Time Frame: From enrollment to primary completion of study (up to approximately 5 years)] [Designated as safety issue: ]
Trough plasma PK (Cmin) of rucaparib based on sparse sampling [Time Frame: From enrollment to primary completion of study (up to approximately 5 years)] [Designated as safety issue: ]
Number of participants with Adverse Events (AEs) as a measure of safety and tolerability [Time Frame: From enrollment to primary completion of study (up to approximately 5 years)] [Designated as safety issue: ]